May 2014

One of NIDA’s goals is to try to understand the individual differences that contribute to whether or not someone who takes a drug will become addicted to it. Dr. Rutter’s research focuses on three types of differences: Environmental, developmental, and genetic and epigenetic.

Dr. Elizabeth F. Howell

Audio

Listen Now:

Length: 02.27 minutes | Download the MP3 (1.68 MB)

Video

Transcript

So as a member of the council, I’m supposed to go to the meetings three times a year, and in between our meetings, we will have some times that we review proposals—grant proposals that have already gone through a first level of review.

The bottom line is, we have to concur or not with what the first-level of review people have done, you know, do we really concur with the decisions of the review committee?

But, we also get to comment on things like, are there concerns about human subjects, are there concerns about animal research, etcetera, etcetera.

September 2013

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

April 2013

The chief of NIDA's Services Research Branch talks about drug abuse treatment within the criminal justice system, and assesses the challenges facing drug abuse treatment overall in the United States.

November 2012

NIDA Program Officer Dr. David Thomas speaks about the intertwined problems of pain and prescription opioid abuse, as well as the research supported by NIDA and the National Institutes of Health to address these problems.

April 2012

NIDA’s Women and Sex/Gender Differences Research Program focuses on gender-specific addiction risk factors and treatment needs.

July 2011

Describes NIDA’s Special Populations Office which promotes addiction science that examines health disparities and foster research careers among members of underrepresented communities.

December 2010

Reports on the objectives and activities of the Neuroscience Consortium and their impact on Institute drug abuse research programs and initiatives.

April 2010

Highlights NIDA’s research portfolio to identify the genes and genetic processes responsible for a person’s vulnerability to drug abuse.

November 2009

Discusses the work of NIDA’s Division of Epidemiology, Services and Prevention Research, organized to track drug use and provide empirically based information for researchers and service providers.

Pages

-->